文献速递贫血与红细胞疾病

沙利度胺1 vs 2 mg/kg/d治疗输血依赖型地中海贫血的非劣效性试验

Efficacy and safety of thalidomide (1 vs 2 mg/kg/d) in transfusion-dependent thalassemia: A Non-Inferiority Trial.
PubMed 文献 · Blood Adv · 2026-09-01

该前瞻性随机开放标签多中心试验在印度4个中心比较沙利度胺1 mg/kg/d与2 mg/kg/d对≥12岁输血依赖型地中海贫血患者的疗效与安全性。主要终点第24周输血需求减少率在1 mg/kg/d组显著更高(67.1% vs 50.0%,p=0.012),总体应答率58.5%,提示低剂量非劣效且安全性可接受。

要点

  • 沙利度胺1 mg/kg/d组第24周总体应答率显著高于2 mg/kg/d组(67.1% vs 50.0%,p=0.012)。
  • 总体应答率58.5%,良好应答20.5%、中度应答37.8%、无应答41.6%,9例(5.6%)达输血独立。
  • 因毒性停药者占10.6%,不良事件多为1级,低剂量方案在资源有限地区可行。

核心结论

  • 沙利度胺1 mg/kg/d在减少输血依赖型地中海贫血患者输血负担方面非劣效于2 mg/kg/d,且安全性可接受。

研究设计与样本

  • 前瞻性、随机、开放标签、多中心临床试验,在印度4个中心开展。
  • 纳入≥12岁输血依赖型地中海贫血患者188例,每组94例,82.4%完成第24周评估。
  • 比较沙利度胺1 mg/kg/d(组1)与2 mg/kg/d(组2),主要终点为第24周输血需求减少程度。

主要发现

  • 总体应答率58.5%,组1显著高于组2(67.1% vs 50.0%,p=0.012)。
  • 良好应答、中度应答、无应答分别占20.5%、37.8%、41.6%,9例(5.6%)达输血独立。
  • 良好应答者中71.8%在12周内出现临床获益,中度应答者100%在12周内出现获益。
  • 第72周持续应答率在组1和组2初始应答者中分别为49%和57.5%。
  • 不良事件多为1级,10.6%参与者因毒性需停药。

关键数值与推荐

  • 应答分类:良好为输血需求减少>50%,中度为25-50%,无应答为<25%。
  • 第24周总体应答率58.5%,组1为67.1%,组2为50.0%(p=0.012)。
  • 第72周持续应答率:组1为49%,组2为57.5%。
  • 因毒性停药率10.6%。

临床怎么用

  • 低剂量沙利度胺(1 mg/kg/d)可作为资源有限地区输血依赖型地中海贫血的可行治疗选择。
  • 治疗中需每4周进行安全性评估,关注毒性所致停药。
  • 应答者可在第25-72周逐步减量以评估应答可持续性。

局限性

  • 开放标签设计可能引入偏倚。
  • 仅82.4%完成第24周评估,存在数据缺失。
  • 随访至第72周,长期疗效与安全性未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thalidomide has emerged as a fetal hemoglobin-inducer with potential to reduce transfusion burden in transfusion-dependent thalassemia (TDT). However, optimal dosing remains undefined A prospective, randomized, open-label, multicentric clinical trial was conducted at four centres in India to compare efficacy and safety of thalidomide at 1 mg/kg/day (Group 1) versus 2 mg/kg/day (Group 2) in patients with TDT aged ≥12 years. The primary endpoint was reduction in transfusion requirement at week 24, categorized as good (>50%), moderate (25-50%), or no (<25%) response. Responders underwent stepwise dose tapering during weeks 25-72 to evaluate response sustainability. Safety assessments were performed every 4 weeks. Of 188 enrolled patients (94 per group), 82.4% completed the week-24 evaluation. The overall response rate (ORR) was 58.5%, significantly higher in Group 1 than Group 2 (67.1% vs 50.0%, p=0.012). Good, moderate, and no response were observed in 20.5%, 37.8%, and 41.6% of patients, respectively, with transfusion independence in 9 patients (5.6%). Clinical benefit was observed within 12 weeks in 71.8% of good responders and 100% moderate responders. Sustained response at week 72 was seen in 49% and 57.5% of initial responders in Groups 1 and 2, respectively. Adverse effects were mostly grade 1; drug discontinuation due to toxicity was required in 10.6 % participants. These findings suggest that Thalidomide at 1 mg/kg/day was non-inferior to 2 mg/kg/day in reducing transfusion burden in patients with TDT, with an acceptable safety profile. Low-dose thalidomide appears to be a feasible treatment option in resource-limited settings. ICMR trial registry (Trial no. CTRI/2022/05/042781).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kakkar S, Mahajan A, Sharma RA, et al. Efficacy and safety of thalidomide (1 vs 2 mg/kg/d) in transfusion-dependent thalassemia: A Non-Inferiority Trial. Blood Adv. 2026. PMID: 42679337. doi:10.1182/bloodadvances.2025019459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。